Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9205MR)

This product GTTS-WQ9205MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9205MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3754MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ3457MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ13616MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ15019MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ4387MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ873MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ13701MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ14332MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG7414
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW